2023 World Conference on Lung Cancer (Posters)-EP11.01. Neutrophil to Lymphocite Ratio in Patients Treated with Immunotherapy after Progression on Chemotherapy

EP11.01. Neutrophil to Lymphocite Ratio in Patients Treated with Immunotherapy after Progression on Chemotherapy - PDF(Abstract)

Back to course

Pdf Summary

A study presented at the WCLC 2023 conference investigated the use of the neutrophil-to-lymphocyte ratio (NLR) as a potential biomarker for predicting outcomes in patients with metastatic non-small cell lung cancer (NSCLC) treated with immunotherapy after chemotherapy. The researchers conducted a retrospective cohort study of 105 patients treated with nivolumab, a type of immunotherapy, and analyzed their NLR levels. They found that patients with a low NLR had significantly better overall survival compared to those with a high NLR. However, there was no significant difference in progression-free survival between the two groups. The study suggests that indicators of systemic inflammation, such as the NLR, may be associated with overall survival in pre-treated NSCLC patients receiving immunotherapy. The study acknowledges the limitation of a small sample size but highlights the importance of real-life data in understanding the use of biomarkers in clinical practice.

Asset Subtitle

Marko Jakopovic

Meta Tag

Speaker Marko Jakopovic

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

neutrophil-to-lymphocyte ratio

NLR

biomarker

predicting outcomes

metastatic non-small cell lung cancer

NSCLC

immunotherapy

chemotherapy

overall survival

progression-free survival